Abstract

Mission

The PREDICCt consortium will combine the latest insights into the causes of Type 2 diabetes mellitus (DM2) with innovative technologies to identify risk-indicators (biomarkers) for DM2 and DM2-related complications, in order to enable (a) stratification of patients at risk of developing diabetes and its cardiovascular complications and (b) development of molecular diagnostics and molecular imaging to identify patients at risk.

Links/Social Media Feed

Other website  http://www.ctmm.nl/en/projecten/hartvaat/predicct

Points of Contact
Marten Hofker  
Principal Investigator, PREDICCT project  
University Medical Center Groningen (UMCG)

Erna Erdtsieck-Ernste  
Program Manager, Cardiovascular Disease  
phone: +31 (0)40 800 23 06

Sponsors & Partners

BG Medicine NV  
Da Vinci Europe Laboratory Solutions  
Diagnostics  
Eindhoven University of Technology  
Fabpulous  
Hycult Biotech  
Leiden University Medical Center  
Maastricht University Medical Center  
Medipark  
MicroScan  
MSD Oss  
Nefrovisie  
Nutricia Research  
Oroboros Instruments GmbH  
Percuros BV  
Radboudumc  
Spinnovation  
TNO: Netherlands Organisation for Applied Scientific Research  
TOPIC Embedded Systems  
University Leiden  
University Medical Center Groningen (UMCG)  
University Medical Center Utrecht  
U-Protein Express BV